Conflict of interest Dr. Hendriks and Dr. van de Kerkhof participated in a trial funded by Basilea Pharmaceutica. Dr. de Jong served as consultant for and participated in research with Biogen, Serono, Wyeth, and Abbott. Dr. Seyger has served as a consultant for Wyeth, Pfizer, and Abbott and received grants from Pfizer and LEO Pharma. Dr. van de Kerkhof served as consultant for Schering Plough, Cellgene, Centocor, Allmirall, UCB, Wyeth, Pfizer, Soffinova, Abbott, Actelion, Galderma, Novartis, Janssen Cilag and LEO Pharma. He also received research grants form Centocor, Wyeth, Schering Plough, Merck Serono, Abbott, Philips Lighting, Pfizer, Janssen Cilag, and LEO Pharma.
Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review
Article first published online: 11 JUL 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 4, pages 399–410, April 2013
How to Cite
Hendriks, A.G.M., Keijsers, R.R.M.C., de Jong, E.M.G.J., Seyger, M.M.B. and van de Kerkhof, P.C.M. (2013), Combinations of classical time-honoured topicals in plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 27: 399–410. doi: 10.1111/j.1468-3083.2012.04640.x
Funding sources This systematic review was funded by LEO Pharma. LEO Pharma played no role in the design and conduct of the study or in the data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review or manuscript approval.
- Issue published online: 18 MAR 2013
- Article first published online: 11 JUL 2012
- Received: 18 April 2012; Accepted: 11 June 2012
Background Despite the availability of newer topical treatments, classical topical treatments for chronic plaque psoriasis still have an important position for selected patient populations. The vast majority of patients are treated with a combination of topicals. The question arises: what is the evidence behind these approaches?
Objectives To systematically review all available literature on efficacy and safety of combinations of classical topical treatments in chronic plaque psoriasis, including all combinations with dithranol, coal tar and penetration enhancers, and ultimately, to propose recommendations for combination treatment.
Methods Standardized literature searches in PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register, and allocation of the degree of evidence was carried out.
Results In total 2918 publications on topical combination therapy were revealed, of which 48 articles on combinations of classical treatments. In this article, the results concerning the 19 included publications are stated. The majority of combination regimens is at least as effective as monotherapies, and is generally well tolerated.
Conclusions Methods of classical treatments are not standardized and different protocols in different treatment settings are used. Therefore the interpretation of study results cannot be generalized. Most evidence was found to recommend the use of a combination regimen of topical corticosteroids and salicylic acid, above monotherapy with either component. Also, the combinations of dithranol with superpotent corticosteroids or with coal tar may be preferred above both monotherapies. In case first-line treatments and systemic therapies are not effective or contraindicated, combinations of classical topicals may provide an important opportunity.